Clinical data | |
---|---|
Other names | GSK2140944 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider | |
UNII | |
KEGG | |
ECHA InfoCard | 100.249.088 |
Chemical and physical data | |
Formula | C24H28N6O3 |
Molar mass | 448.527 g·mol−1 |
3D model (JSmol) | |
| |
|
Gepotidacin (INN[1]) is an experimental antibiotic that acts as a topoisomerase type II inhibitor.[2] It is being studied for the treatment of uncomplicated urinary tract infection (acute cystitis)[3] and infection with Neisseria gonorrhoeae (gonorrhea), including multidrug resistant strains.[4][5]
In October 2024, gepotidacin was granted priority review by the US Food and Drug Administration (FDA) for the treatment of uncomplicated urinary tract infections.[6]
References
- ^ "International Nonproprietary Names for Pharmaceutical Substances" (PDF). WHO Drug Information. 28 (4). 2014.
- ^ Biedenbach DJ, Bouchillon SK, Hackel M, Miller LA, Scangarella-Oman NE, Jakielaszek C, et al. (January 2016). "In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens". Antimicrobial Agents and Chemotherapy. 60 (3): 1918–1923. doi:10.1128/aac.02820-15. PMC 4776004. PMID 26729499.
- ^ Wagenlehner F, Perry CR, Hooton TM, Scangarella-Oman NE, Millns H, Powell M, et al. (February 2024). "Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials". Lancet. 403 (10428): 741–755. doi:10.1016/S0140-6736(23)02196-7. PMID 38342126. S2CID 267548740.
- ^ Scangarella-Oman NE, Hossain M, Dixon PB, Ingraham K, Min S, Tiffany CA, et al. (December 2018). "Microbiological Analysis from a Phase 2 Randomized Study in Adults Evaluating Single Oral Doses of Gepotidacin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae". Antimicrobial Agents and Chemotherapy. 62 (12). doi:10.1128/AAC.01221-18. PMC 6256812. PMID 30249694.
- ^ Jacobsson S, Golparian D, Scangarella-Oman N, Unemo M (August 2018). "In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR Neisseria gonorrhoeae". The Journal of Antimicrobial Chemotherapy. 73 (8): 2072–2077. doi:10.1093/jac/dky162. PMC 6927889. PMID 29796611.
- ^ "GSK's investigational antibiotic granted FDA priority review for urinary tract infections". PMLiVE. 18 October 2024. Retrieved 21 October 2024.